Zymeworks Inc
NYSE:ZYME
| Market Cap (Intraday) | 1.45B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $31.30 |
| 50-Day MA | $35.65 |
| 200-Day MA | $40.10 |
Zymeworks, Inc. Stock, NYSE:ZYME
1385 West 8th Avenue, Suite 540, Vancouver, British Columbia V6H 3V9
Canada
Phone: +1.604.678.1388
Number of Employees: 256
Description
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.